Literature DB >> 34313931

Endophthalmitis: a bibliographic review.

Christian I Wade1, Todd D Whitescarver2, Cody R Ashcroft3, Samuel D Hobbs4, Boonkit Purt2,5, Ashvini K Reddy6, Marcus H Colyer5,7, Grant A Justin8,9.   

Abstract

PURPOSE: To analyze the 100 most cited articles pertaining to endophthalmitis using bibliometric analysis.
METHODS: An all-time Web of Science literature search and refined to peer-reviewed articles in the field of ophthalmology with the keyword "endophthalmitis" was completed. Total citation count of articles published pertaining to endophthalmitis, topic, incidence rate, publishing journals, year published, language, country of origin, number of authors, names of the first and last authors, study type, and number of patients/eyes studied.
RESULTS: The top 100 most cited articles pertaining to endophthalmitis had a mean citation count of 362.92, with a range of 175 to 3583. They were published in 20 peer-reviewed journals, with Ophthalmology publishing the most (n = 42). Thirteen different countries were represented, with the majority (n = 77) originating from the USA. The most common study type was clinical experiences (n = 52), though eight of the top ten were clinical trials. The number of patients varied widely, represented by a mean of 9680, but with a median of only 229. The majority (n = 67) examined the incidence of endophthalmitis which included 24 articles after anti-vascular endothelial growth factor injections, 18 after ocular surgeries/procedures, 15 after intraocular steroid injections, eight after chemotoxic drug use, and three after ocular injuries.
CONCLUSION: This bibliographic study serves as a unique historical analysis of the top 100 cited scholarly articles pertaining to endophthalmitis with many of the articles related to post-procedural endophthalmitis.
© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Keywords:  Bibliographic review; Cataract surgery; Endophthalmitis; Intravitreal injection; Postoperative endophthalmitis

Year:  2021        PMID: 34313931     DOI: 10.1007/s10792-021-01967-y

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  28 in total

1.  Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

Authors:  Michael J Elman; Lloyd Paul Aiello; Roy W Beck; Neil M Bressler; Susan B Bressler; Allison R Edwards; Frederick L Ferris; Scott M Friedman; Adam R Glassman; Kellee M Miller; Ingrid U Scott; Cynthia R Stockdale; Jennifer K Sun
Journal:  Ophthalmology       Date:  2010-04-28       Impact factor: 12.079

2.  METASTATIC ENDOPHTHALMITIS IN A CASE OF CEREBRO-SPINAL MENINGITIS.

Authors:  A L Weakley
Journal:  Br Med J       Date:  1916-01-08

3.  Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke.

Authors:  David Sacks; Blaise Baxter; Bruce C V Campbell; Jeffrey S Carpenter; Christophe Cognard; Diederik Dippel; Muneer Eesa; Urs Fischer; Klaus Hausegger; Joshua A Hirsch; Muhammad Shazam Hussain; Olav Jansen; Mahesh V Jayaraman; Alexander A Khalessi; Bryan W Kluck; Sean Lavine; Philip M Meyers; Stephen Ramee; Daniel A Rüfenacht; Clemens M Schirmer; Dierk Vorwerk
Journal:  Int J Stroke       Date:  2018-05-22       Impact factor: 5.266

4.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

5.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

Review 6.  Acute endophthalmitis following cataract surgery: a systematic review of the literature.

Authors:  Mehran Taban; Ashley Behrens; Robert L Newcomb; Matthew Y Nobe; Golnaz Saedi; Paula M Sweet; Peter J McDonnell
Journal:  Arch Ophthalmol       Date:  2005-05

7.  The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

Authors:  Paul Mitchell; Francesco Bandello; Ursula Schmidt-Erfurth; Gabriele E Lang; Pascale Massin; Reinier O Schlingemann; Florian Sutter; Christian Simader; Gabriela Burian; Ortrud Gerstner; Andreas Weichselberger
Journal:  Ophthalmology       Date:  2011-04       Impact factor: 12.079

8.  Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

Authors:  Quan Dong Nguyen; David M Brown; Dennis M Marcus; David S Boyer; Sunil Patel; Leonard Feiner; Andrea Gibson; Judy Sy; Amy Chen Rundle; J Jill Hopkins; Roman G Rubio; Jason S Ehrlich
Journal:  Ophthalmology       Date:  2012-02-11       Impact factor: 12.079

9.  Pegaptanib for neovascular age-related macular degeneration.

Authors:  Evangelos S Gragoudas; Anthony P Adamis; Emmett T Cunningham; Matthew Feinsod; David R Guyer
Journal:  N Engl J Med       Date:  2004-12-30       Impact factor: 91.245

10.  Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.

Authors:  David M Brown; Mark Michels; Peter K Kaiser; Jeffrey S Heier; Judy P Sy; Tsontcho Ianchulev
Journal:  Ophthalmology       Date:  2009-01       Impact factor: 12.079

View more
  1 in total

1.  Analysis of antibiotic resistance and genetic profile of conjunctival bacteria flora before and after cataract surgery.

Authors:  Margarita Samudio; Sonia Abente; Norma Fariña; Yolanda López; Carolina Duré; Florentina Laspina; Rosa Guillén; Claudia de Los Ángeles Salinas; Verónica Castillo; Jesús Palacios; Iris Santacruz; Martin Nentwich
Journal:  Int Ophthalmol       Date:  2022-08-09       Impact factor: 2.029

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.